Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical proof-of-concept study with OXP 003 [Safestat™ Atorvastatin]

Trial Profile

Clinical proof-of-concept study with OXP 003 [Safestat™ Atorvastatin]

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 May 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Hyperlipidaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2014 Study title not official; phase assumed. Exact indication unclear.
    • 07 May 2014 New trial record
    • 30 Apr 2014 Oxford Pharmascience has reviewed its proposed initial clinical development programme for OXP 003 with the Medicines and Healthcare Products Regulatory Agency and has appointed Quotient Clinical to conduct the proof-of-concept study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top